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Abstract
Background: Several polymorphisms of genes involved in the immunological recognition of Helicobacter pylori and
regulating apoptosis and proliferation have been linked to gastric carcinogenesis, however reported data are
partially conflicting. The aim of our study was to evaluate potential associations between the presence of gastric
cancer (GC) and high risk atrophic gastritis (HRAG) and polymorphisms of genes encoding Angiotensin converting
enzyme (ACE), Nod-like receptor 1 (NOD1), Toll-like receptor 4 (TLR4) and FAS/FASL.
Methods: Gene polymorphisms were analyzed in 574 subjects (GC: n = 114; HRAG: n = 222, controls: n = 238) of
Caucasian origin. ACE I/D (rs4646994), NOD1 796G>A (rs5743336), TLR4 3725G>C (rs11536889), FAS 1377G>A
(rs2234767), FAS 670A>G (rs1800682) and FASL 844T>C (rs763110) were genotyped by different PCR approaches and
restriction fragment length polymorphism analysis.
Results: Frequencies of genotypes in our study are similar to the data reported on subjects of Caucasian ethnicity.
There was a tendency for NOD1 796G/G genotype to be associated with increased risk of HRAG (62.4% vs. 54.5% in
controls, p = 0.082). FAS 670G/G genotype was more frequent in HRAG when compared to controls, 23.9% and
17.2% respectively, however it failed to reach significance level (p = 0.077). We did not find any significant
associations for all polymorphisms in relation to GC or HRAG. NOD1 796G>A and TLR4 3725G>C gene
polymorphisms were also not associated with Helicobacter pylori infection.
Conclusions: ACE, NOD1, TRL4 and FAS/FASL gene polymorphisms are not linked with gastric carcinogenesis in
Caucasians, and therefore they should not be considered as potential biomarkers for identifying individuals with
higher risk for GC.
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Based on the current paradigm, gastric carcinogenesis is
considered as multistep process involving complex inter-
play between Helicobacter pylori (H. pylori)i n f e c t i o n ,
environmental and host genetic factors [1]. In gastric
carcinogenesis two distinct pathways have been sug-
gested for intestinal and diffuse type of gastric cancer
(GC) (1). Correa et al. [2] demonstrated that H. pylori
infection induces chronic inflammation of the gastric
mucosa, leading to atrophic gastritis (AG) and intestinal
metaplasia (IM), which are regarded as essential predis-
posing factors in intestinal-type GC development. Many
researchers have shown a close relationship between H.
pylori not only for intestinal-type GC, but also for dif-
fuse-type GC [3,4]. Furthermore, although AG and IM
are considered as obligatory predisposing factors in
intestinal-type GC, the accumulating evidence suggests
that AG and IM are at least partially associated with GC
of the diffuse-type as well [3]. Up to date, no molecular
screening methods are available for sporadic GC, there-
fore pathogenetic mechanisms involved in different
stages of gastric carcinogenesis need to be further eluci-
dated to allow identification of individuals with
increased risk for GC. Recent studies have revealed sev-
eral genetic polymorphisms related to immune-recogni-
tion of H. pylori, cell proliferation, and apoptosis
pathways that were linked with premalignant gastric
conditions and GC, but further research is needed to
establish their role in gastric carcinogenesis [5].
Angiotensin I-converting enzyme (ACE) is expressed by
different cell types [6] and generates Angiotensin II,
which is a key effector in renin-angiotensin system.
Recent reports provided evidence that Angiotensin II is
involved in the regulation of cell proliferation, angiogen-
esis and inflammation through the Angiotensin II type 1
receptors, which are expressed on tumor and endothelial
cells [7-9]. Insertion (I) or deletion (D) polymorphism of
ACE gene was shown to have functional relevance, since
the carriers of D allele have higher ACE activity [10].
ACE I/D polymorphism was linked with early develop-
ment and spread of GC [11], but the studies report null
association with the overall risk for GC [12,13]. ACE I/
D polymorphism was not linked with gastric atrophy in
Asian subjects [14]. There are however no reports that
evaluate the role ACE I/D polymorphism in premalig-
nant gastric conditions in Caucasians and studies
addressing the role of ACE I/D polymorphisms in gas-
tric carcinogenesis are limited.
Nucleotide-binding oligomerisation domain 1 (NOD1)
is a member of the Nod-like receptors, which is
expressed in the cytoplasm of antigen presenting cells
and gastric epithelial cells and is involved in recognition
of gram-negative bacteria [15]. It is known that stimula-
tion of gastric epithelial cells with NOD1 ligands leads
to production of proinflammatory cytokines [16,17] and
NOD1 participates in host defense against mucosal
infection with H. pylori infection [17,18]. Recently
NOD1 was found to respond to peptidoglycan delivered
by H. pylori cagPAI [19]. Given the significant role of H.
pylori in gastric carcinogenesis, it is hypothesized that
genetic variations in gene encoding NOD1 receptor
could be related to different outcomes. Gene poly-
morphism 796G>A of NOD1 has been linked with pep-
tic ulcer disease in H. pylori-positive patients [20] and a
significant association with very high odds ratios has
been recently reported for the risk of premalignant
lesions in the antrum of the stomach [21]. Up to date,
t h ed a t ao nNOD1 796G>A gene polymorphism remain
very scarce and there are no reports concerning the role
of this polymorphism in patients with GC.
Another important receptor for the recognition of H.
pylori is Toll-like receptor 4 (TLR4), a member of Toll-like
receptors family. TLR4 recognizes lipopolysaccharide of
gram-negative bacteria, and it is thought to interact with
macrophage/monocyte in response to H. pylori infection
[22]. Expression of TLR4 by gastric epithelium is upregu-
lated in H. pylori-induced gastritis compared to non-
inflamed gastric mucosa [23]. Single nucleotide polymorph-
isms (SNPs) of TLR4 gene are thought to disrupt the nor-
mal structure of the extracellular region of the TLR4 and
are therefore hypothesized to decrease responsiveness to
lipopolysaccharide through alterations in binding. TLR4
896A>G polymorphism was found to be associated with
higher risk of H. pylori-induced GC and its precursors [24].
Recently, a novel polymorphism in TLR4 gene 3725G>C
(rs11536889) with functional relevance was identified [25]
and linked with severe gastric atrophy in Asian population
[26]. This is however the only report on TLR4 3725G>C
polymorphism and the potential link with premalignant
gastric lesions or GC has not been evaluated yet.
The role of apoptosis in tumor genesis has been well
established [27]. The FAS and FASL system plays an
important role in regulating apoptotic cell death, initiat-
ing the extrinsic pathway of apoptosis [28]. Decreased
expression levels of FAS and FASL are associated with
different malignancies as well as the progression of gas-
tric carcinoma [29]. Several single nucleotide poly-
morphisms (SNPs) FAS 1377G>A (rs2234767), FAS
670A>G (rs1800682) and FASL 844T>C (rs763110) were
shown to affect gene expression [30,31]. Liu et al.
showed an association between these FAS/FASL gene
polymorphisms and higher risk of GC [32], while other
studies reported null associations [33,34]. These poly-
morphisms were also associated with the risk of atrophic
gastritis [35], however the data published on the associa-
tion with risk for GC are still scarce and there are no
reports on the role FAS/FASL polymorphisms with
respect to GC in Caucasians.
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Page 2 of 9Given the pathophysiological significance of ACE,
NOD1, TLR4, FAS and FASL genes in gastric carcino-
genesis, it is intriguing to assess the role of these poly-
morphisms for the development of GC and H. pylori-
associated premalignant gastric lesions. Therefore, the
aim of our study was to evaluate potential links between
t h ep r e s e n c eo fG Co rH R A Ga n dACE I/D, NOD1
796G>A, TLR4 3725G>C, FAS 1377G>A, FAS 670A>G
and FASL 844T>C gene polymorphisms in 114 patients
with GC, 222 patients with HRAG and 238 controls of
Caucasian origin. This study provides further insights in
the puzzle of genetic susceptibility for GC and its
precursors.
Methods
Study population
Subjects included in the study came from our previous
research groups on IL-1B, IL-1RN and NOD2 gene poly-
morphisms [36-38]. Patients were recruited at three gas-
troenterological centers in Germany, Lithuania and
Latvia. In Germany, patients with GC, HRAG and healthy
controls were recruited from the Department of Gastro-
enterology of the Otto-von-Guericke University Magde-
burg between 1998 and 2008. Patients with HRAG were
included from the Out-patient Department, and from a
clinical study aimed at the long-term follow up of H.
pylori infection. Controls were recruited from clinical
studies with healthy volunteers and subjects from the
Out-patient Department with dyspeptic symptoms.
In Lithuania and Latvia, patients with HRAG and con-
trols were included from the Out-patient Departments
of University Hospitals in Kaunas and Riga. All the indi-
viduals were referred for upper endoscopy because of
dyspeptic symptoms during the period of 2005-2006.
The inclusion criteria of HRAG and controls were no
history of malignancy, gastrointestinal disease or sur-
gery. GC was determined by histology. From all partici-
pants, DNA for genotyping was available. In total, 346
individuals (114 GC, 140 HRAG, 92 controls) from Ger-
many and 228 individuals from Lithuania and Latvia (82
HRAG, 146 controls) were included. All patients were
of Caucasian ethnicity. The study was approved by the
Ethics Committees of the OvG University Magdeburg,
Lithuanian University of Health Sciences and University
of Latvia, and informed consent to participate in the
study was obtained from all subjects included.
Histological analysis and H. pylori status
Scoring of atrophic gastritis and intestinal metaplasia
was done according to the modified Sydney classifica-
tion [39]. Histological evaluation for GC type was car-
ried out according to the Laurén classification [40].
HRAG was defined as pan-gastritis (similar inflamma-
tory scores in antrum and corpus), corpus-predominant
gastritis with or without the presence of gastric atrophy,
and intestinal metaplasia either in antrum or corpus as
described by Uemura et al. and Meining et al. [41,42].
H. pylori status was determined by testing for anti-H.
pylori IgG antibodies in sera.
Genotyping
Genomic DNA was extracted from peripheral blood
mononuclear cells using the QIAamp DNA blood kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions.
ACE I/D
The ACE I/D genotype (rs4646994) was determined by
PCR using primers: forward 5’-CTGGAGACCACTCC-
CATCCTTTCT-3’ and reverse, 5’-GATGTGGCCAT-
CACATTCGTCAGAT-3’. An initial 15 minute
denaturation at 95° was followed by 40 cycles of 1 min
at 64°C, 1 min at 72°C, and 35 s at 95.5°C. Amplified
ACE gene polymorphisms were separated on 1.0% agar-
ose gels, and visualized by ethidium bromide staining. D
and I alleles were determined by the presence of 190 or
490 bp fragments (Figure 1).
Figure 1 Gene polymorphisms were determined by DNA fragment migration profile on agarose gel and visualized by ethidium
bromide staining: A. ACE I/D genotypes: D or I alleles were identified by the presence of 190 or 490 bp fragments B. NOD1 796G>A
genotypes: wild-type DNA is visible as a double-band 209 bp and 170 bp (GG); the mutated DNA is visible as a single 379 bp band
(AA); heterozygotes give three bands (GA); C. TLR4 3725G>C genotypes: wild-type is visible as a double-band 184 and 397 bp (GG),
mutated DNA is visible as 256 and 397 bp bands (CC); heterozygotes give three bands 184, 256, and 397 bp bands (GC). Lane L is a
100 bp molecular weight marker (HyperLadder IV, Bioline GmbH, Berlin, Germany).
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The NOD1 796G>A SNP (rs5743336) was analyzed by
PCR restriction fragment length polymorphism analysis
(PCR-RFLP) with the following primers: forward 5’-TGA
GAC CAT CTT CAT CCT GG-3’; reverse 5’-CTT CCC
ACT GAG CAG GTT G-3’. An initial 15 minute dena-
turation at 95° was followed by 40 cycles of 1 min at 64°
C, 1 min at 72°C, and 35 s at 95.5°C. For RFLP analysis,
the PCR products were digested with AvaI restriction
enzyme (Fermentas, Vilnius, Lithuania) at 37°C over-
night, studied by gel electrophoresis on a 2% agarose gel
and visualized with ethidium bromide staining. The pre-
sence of G allele was indicated by cleavage of the 379
bp amplified PCR product to yield fragments of 209 bp
and 170 bp (Figure 1).
TLR4 3725G>C
The TLR4 3725G>C SNP (rs11536889) was genotyped
using confronting two-pair primers PCR (PCR-CTPP).
The primers were F1: TTT GAT GGA CCT CTG AAT
CTC, R1: TTT TCT CAA TGA TAA CAT CCA CTC,
F2: CTT GAC CAC ATT TTG GGA AC, and R2: TTC
CAA TTT CTC TAT ATC CTT GAT GA. An initial
15 minute denaturation at 95° was followed by 40 cycles
of 1 min at 64°C, 1 min at 72°C, and 35 s at 95.5°C. The
amplified DNA was visualized on a 2% agarose gel with
ethidium bromide staining. The amplified DNA was 184
bp for G allele, 256 bp for C allele, and 397 bp for com-
mon band (Figure 1).
FAS 1377G>A, FAS 670A>G, FASL 844T>C
SNPs of FAS 1377G>A (rs2234767), FAS 670A>G
(rs1800682) and FASL 844T>C (rs763110) were geno-
typed by using predesigned TaqMan assays with a
BioRad CFX96™ real-time cycler, in accordance with
the manufacturer’s instructions (Bio-Rad Laboratories
Inc, Hercules, USA). Thermal cycling conditions for
polymerase chain reaction (PCR) were, first, denaturing
at 95°C for 10 min, followed by 40 cycles of 95.5°C for
15 s and 60°C for 1 min (Figure 2).
Statistical analysis
Concordance of genotype frequencies with the Hardy-
Weinberg equilibrium was tested by online software
http://ihg.gsf.de/cgi-bin/hw/hwa1.pl. Age is shown as
means and standard deviations, and was compared using
ANOVA and unpaired Student’s t-test. Categorical data
(e.g. gender, distribution of genotypes or alleles) are pre-
sented as frequencies; comparisons were performed
using the Chi-square test. Association between HRAG
and GC with gene polymorphisms were calculated using
unconditional multiple logistic regression analysis and
expressed as odds ratios (OR) with 95% confidence
intervals (CI). The ORs presented in the study were not
adjusted for confounding factors. The relative risks for
mutations were studied using recessive and dominant
model that led to a comparison between wildtype+het-
erozygous vs. homozygous and wildtype vs. heterozy-
gous+homozygous, respectively. Statistical analysis was
done using statistical software SPSS Version 16.0 (SPSS
Inc., Chicago, Illinois, USA).
Results
The characteristics of the study groups are presented in
Table 1. German and Baltic study groups did not differ
significantly according to the allele distribution (data
not shown), therefore the respective groups with HRAG
as well as controls were combined and further analyzed
together. Patients differed significantly according to age
and gender distribution. Male made up for almost 2/3
of patients with GC, while both other groups demon-
strated inverse findings. Furthermore, controls were sig-
nificantly younger (6 or 9 years) than both other groups
(Table 1). Notably, serological H. pylori status were
Figure 2 Gene polymorphisms of FAS 1377G>A, FAS 670A>G
and FASL 844T>C were determined using Taqman genotyping
assays with Biorad CFX96™ real-time cycler (Bio-Rad
Laboratories Inc, Hercules, USA).
Table 1 Characteristics of groups
Controls
(n = 238)
GC
(n = 114)
HRAG
(n = 222)
ANOVA (Age)
Chi-squared
test
p value
Age
Mean ±
SD
56.9 ±
16.1
65.51 ±
13.4
63.4 ±
10.4
< 0.001
Gender
Male 79 (33.2%) 77 (67.5%) 87 (39.2%) < 0.001
Female 159
(66.8%)
37 (32.5%) 135
(60.8%)
H. pylori
Positive 141
(59.2%)
70 (61.4%) 133
(59.9%)
0.928
Negative 97 (40.8%) 44 (38.6%) 89 (40.1%)
Statistical analysis was performed globally for all three groups.
GC, gastric cancer; HRAG, high risk atrophic gastritis
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pylori-positive subjects was between 59-62%, and did
not differ significantly.
All individuals were successfully genotyped for ACE I/
D, FAS 1377G>A, FAS 670A>G and FASL 844T>C
polymorphisms. Four subjects were not genotyped for
NOD1 796G>A polymorphism and five subjects for
TLR4 3725G>C polymorphism. The genotype distribu-
tions for all six polymorphisms in control, HRAG and
GC groups were similar to those expected for Hardy-
Table 2 Association of ACE, NOD1, TLR4, FAS and FASL gene polymorphisms with gastric cancer and high risk atrophic
gastritis
Genotypes Controls (n = 238) GC (n = 114) HRAG (n = 222)
n (%) n (%) OR (95% CI) p n (%) OR (95% CI) p
ACE I/D
I/I 62 (26.1) 27 (23.7) 0.88 (0.52-1.48) 0.632 62 (27.9) 1.10 (0.73-1.66) 0.650
I/D 110 (46.2) 59 (51.8) 1.25 (0.79-1.95) 0.331 108 (48.6) 1.10 (0.76-1.59) 0.602
D/D 66 (27.7) 28 (24.6) 0.85 (0.51-1.42) 0.529 52 (23.4) 0.79 (0.52-1.21) 0.290
Allele I 234 (49.2) 113 (49.6) 1.02 (0.74-1.39) 0.921 232 (52.3) 1.13 (0.87-1.47) 0.348
Allele D 242 (50.8) 115 (50.4) 0.98 (0.72-1.35) 0.921 212 (47.7) 0.88 (0.68-1.15) 0.348
NOD1 796G>A
G/G 129 (54.4) 61 (54.5) 1.00 (0.64-1.57) 0.995 138 (62.4) 1.39 (0.96-2.02) 0.082
G/A 85 (35.9) 40 (35.7) 0.99 (0.62-1.59) 1.000 66 (29.9) 0.76 (0.52-1.13) 0.172
A/A 23 (9.7) 11 (9.8) 1.01 (0.48-2.16) 0.973 17 (7.7) 0.78 (0.40-1.49) 0.446
Allele G 343 (72.4) 162 (72.3) 0.99 (0.70-1.42) 0.991 342 (77.4) 1.31 (0.97-1.76) 0.081
Allele A 131 (27.6) 62 (27.7) 1.00 (0.70-1.73) 0.991 100 (22.6) 0.77 (0.57-1.03) 0.081
TLR4 3725G>C
G/G 190 (80.5) 90 (79.6) 0.95 (0.54-1.66) 0.849 181 (82.3) 1.12 (0.70-1.80) 0.629
G/C 41 (17.4) 21 (18.6) 1.09 (0.61-1.94) 0.782 33 (15.0) 0.84 (0.51-1.38) 0.492
C/C 5 (2.1) 2 (1.8) 0.83 (0.16-4.36) 0.832 6 (2.7) 1.29 (0.39-4.31) 0.672
Allele G 421 (89.2) 201 (88.9) 0.97 (0.59-1.62) 0.919 395 (89.8) 1.06 (0.69-1.62) 0.776
Allele C 51 (10.8) 25 (11.1) 1.03 (0.62-1.71) 0.919 45 (10.2) 0.94 (0.62-1.44) 0.776
FAS 1377G>A
G/G 197 (82.8) 95 (83.3) 1.04 (0.57-1.88) 0.895 178 (80.2) 0.84 (0.52-1.35) 0.471
G/A 40 (16.8) 18 (15.8) 0.92 (0.51-1.70) 0.809 41 (18.5) 1.12 (0.69-1.81) 0.640
A/A 1 (0.4) 1 (0.9) 2.09 (0.13-33.8) 0.593 3 (1.4) 3.2 (0.33-31.4) 0.282
Allele G 434 (91.2) 208 (91.2) 1.00 (0.57-1.75) 0.981 397 (89.4) 0.82 (0.52-1.27) 0.366
Allele A 42 (8.8) 20 (8.8) 0.99 (0.56-1.73) 0.981 47 (10.6) 1.22 (0.79-1.90) 0.366
FAS 670A>G
A/A 70 (29.4) 31 (27.2) 0.89 (0.54-1.47) 0.666 68 (30.6) 1.06 (0.71-1.57) 0.775
A/G 127 (53.4) 62 (54.4) 1.04 (0.66-1.63) 0.856 101 (45.5) 0.72 (0.51-1.05) 0.091
G/G 41 (17.2) 21 (18.4) 1.08 (0.60-1.94) 0.783 53 (23.9) 1.50 (0.95-2.39) 0.077
Allele A 267 (56.1) 124 (54.4) 0.93 (0.68-1.28) 0.699 237 (53.4) 0.89 (0.69-1.16) 0.408
Allele G 209 (43.9) 104 (45.6) 1.07 (0.78-1.47) 0.699 207 (46.6) 1.12 (0.86-1.44) 0.408
FASL 844T>C
T/T 124 (52.1) 55 (48.2) 0.86 (0.55-1.34) 0.498 108 (48.6) 0.87 (0.60-1.25) 0.459
T/C 94 (39.5) 52 (45.6) 1.28 (0.81-2.01) 0.275 91 (41.0) 1.06 (0.73-1.54) 0.743
C/C 20 (8.4) 7 (6.1) 0.71 (0.29-1.73) 0.455 23 (10.4) 1.26 (0.67-2.36) 0.471
Allele T 342 (71.8) 162 (71.1) 0.96 (0.67-1.36) 0.826 307 (69.1) 0.87 (0.66-1.17) 0.368
Allele C 134 (28.2) 66 (28.9) 1.04 (0.73-1.47) 0.826 137 (30.9) 1.14 (0.86-1.51) 0.368
GC, gastric cancer; HRAG, high risk atrophic gastritis, CI, confidence interval; OR, odds ratio The ORs were calculated comparing each genotype vs. the other two
genotypes, the first line for each gene polymorphism represents the dominant model and third line represents the recessive model.
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frequencies of ACE I/D, NOD1 796G>A, TLR4
3725G>C, FAS 1377G>A, FAS 670A>G and FASL
844T>C among different groups are presented in Table
2. Analysis of genotypes and allele frequencies showed
similar distribution between GC, HRAG, and controls.
We did not find any significant association between all
polymorphisms included ino u rs t u d yw i t hr e s p e c tt o
GC and HRAG. We also performed an analysis compar-
ing control group with a risk group (combined GC and
HRAG subjects); however it did not reveal significant
differences in genotype frequencies (Additional file 1,
Table S1).
We observed a tendency for NOD1 796G/G genotype
for increased risk of atrophic gastritis (62.4% vs. 54.5%
in controls, p = 0.082). Similarly, NOD1 allele G was
more common in patients with HRAG (77.4%) when
compared to controls (72.4%), but without significance
(p = 0.081). FAS 670G/G genotype was more frequent
in HRAG group when compared to controls, 23.9% and
17.2% respectively, however it failed to reach signifi-
cance level (p = 0.077). The FAS 670G/A genotype was
less frequent in HRAG (45.5%) when compared to con-
trols (53.4%), but the difference was not statistically sig-
nificant (p = 0.091).
We also analyzed the distribution of genotypes with
respect to different histological GC types (Additional file
2, Table S2). Histological type of GC was intestinal, dif-
fuse and mixed type in 47, 47 and 20 patients, respec-
tively. In order to compare intestinal and diffuse type
GC, mixed tumor types were excluded from subanalysis.
ACE D/D polymorphism was found to be less prevalent
in diffuse type GC, when compared to controls (27.7%
vs. 12.8%, respectively; OR-0.38, 95% CI 0.15-0.94, p =
0.030). There were no differences between different his-
tological subtypes of GC with respect to the other gene
polymorphisms. We also analyzed the seropositivity sta-
tus of H. pylori with respect to TLR4 3725G>C and
NOD1 796G>A polymorphisms, but no significant dif-
ferences in genotype distribution were observed (Table
3).
Discussion
Overall, in our study ACE I/D, NOD1 796G>A, TLR4
3725G>C, FAS 1377G>A, FAS 670A>G and FASL
844T>C gene polymorphisms were not associated with
t h ep r e s e n c eo fG Co rH R A G .H e r e ,w ee v a l u a t e ds i x
genetic polymorphisms related to the immune-recogni-
tion of H. pylori, proliferation and apoptosis that were
previously described to be associated with increased risk
of GC or premalignant gastric lesions in different case-
control studies; however reported data are partially con-
flicting or just based on one study
[11-14,20,21,26,33-35]. Since ACE, NOD1, TLR4, FAS,
and FASL have been shown to be involved in gastric
carcinogenesis pathways, we expected that the poly-
morphisms of genes encoding these proteins could be
related to GC.
When analyzing ACE I/D polymorphism we hypothe-
sized that carriers of D allele, which was associated with
higher ACE activity [10], could have an increased risk of
GC. Ebert et al. [11] identified an association of ACE D/
D genotype with the development of early GC, and the
same group of researchers showed that this genotype is
related to the number of metastatic lymph nodes in GC,
but not to the overall risk for GC in German subjects
[12]. A Japanese study did not find an association
between ACE I/D polymorphism and suseptibility to GC
[13]. Another Asian study [14] reported that ACE I/D
polymorphism carried a higher risk for GC with odds
ratio of 1.59, however the same study did not find sig-
nificant association of ACE polymorhisms with gastric
atrophy. ACE I/D genotype frequencies in our study are
in line with previous reports [12]. We did not observe
significant link between ACE I/D polymorphisms and
the risk for GC or HRAG.
Considering the relationship between H. pylori-
induced chronic inflammation and carcinogenesis in the
stomach it was tempting to speculate that genetic varia-
tion in NOD1 receptor, which is involved in bacterial
recognition, could be associated with H. pylori-induced
diseases. NOD1 796A/A homozygous mutants were
linked with increased risk for peptic ulcer disease in a
Hungarian study [20]; however they did not find a sig-
nificant association with atrophic gastritis. A recent
Table 3 Distribution of NOD1 and TLR4 gene
polymorphisms in Helicobacter pylori positive and
negative subjects
Genotypes Hp negative Hp positive
n (%) n (%) OR (95% CI) p
NOD1 796G>A
G/G 133 (57.8) 195 (57.4) 0.98 (0.69-1.37) 0.910
G/A 75 (32.6) 116 (34.1) 1.07 (0.75-1.52) 0.708
A/A 22 (9.60) 29 (8.50) 0.88 (0.49-1.57) 0.670
Allele G 341 (74.1) 506 (74.4) 1.01 (0.77-1.33) 0.915
Allele A 119 (25.9) 174 (25.6) 0.98 (0.75-1.29) 0.915
TLR4 3725G>C
G/G 182 (79.1) 279 (82.3) 1.22 (0.80-1.87) 0.343
G/C 44 (19.1) 51 (15.0) 0.74 (0.48-1.16) 0.199
C/C 4 (1.8) 9 (2.7) 1.54 (0.46-5.06) 0.549
Allele G 408 (88.7) 609 (89.8) 1.12 (0.76-1.64) 0.545
Allele C 52 (11.3) 69 (10.2) 0.88 (0.60-1.30) 0.545
Hp, Helicobacter pylori; OR, odds ratio
The ORs were calculated comparing each genotype vs. the other two
genotypes, the first line for each gene polymorphism represents the dominant
model and third line represents the recessive model.
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Page 6 of 9study from Turkey [21] found that subjects with NOD1
796A/A genotype had a significantly increased risk for
gastric atrophy and antral intestinal metaplasia with very
high odds ratios, 34.2 and 39.7 respectively. Such a
strong association reported by Kara et al. [21] urged us
to evaluate the possible association of this polymorph-
ism in our subjects with GC and HRAG. The genotype
frequencies of NOD1 796G>A in this study correspond
to previous reports [20,21]. In our study we observed a
tendency for NOD1 796G/G genotype and allele G for
increased risk for atrophic gastritis; however the differ-
ence did not reach statistical significance. We did not
observe an association between NOD1 796G>A gene
polymorphism and HRAG or GC. H. pylori seropositiv-
ity status was also not linked with NOD1 796G>A
genotypes.
Polymorphisms of TLR4 gene are hypothesized to
decrease responsiveness to gram-negative bacteria lipo-
polysaccharide through alterations in binding. In a
recent study TLR4 3725G>C polymorphism was indenti-
fied as a risk factor for severe gastric atrophy in H.
pylori sero-positive Japanese subjects with OR of 1.43
and 1.47 for G/C and C/C genotypes, respectively [26],
however in the same study this polymorphism was not
associated with the risk for GC. Another study showed a
combined effect of TLR4 3725G>C and miR-146a G>C
gene polymorphisms for risk of gastric atrophy, but not
f o rG C[ 4 3 ] .O u rd a t ao nTLR4 3725G>C genotype fre-
quencies are comparable to the reported frequencies in
leukemia study on Caucasian population [44]. We did
not find significant association between TLR4 3725G>C
genotypes and HRAG or GC. There was also no associa-
tion between H. pylori seropositivity and TLR4
3725G>C genotypes.
There are only few studies that have evaluated the
risk for GC in relation to FAS and FASL gene poly-
morphisms. Reported results are conflicting and cover
Asian subjects only. In two Chinese case-control stu-
dies FAS and FASL genotypes had no significant asso-
ciations with risk of GC [33,34]. Another study from
China suggested that FASL 844T/T or T/C and FAS
1377A/A genotypes could be a risk factor for GC in
combination with other gene polymorphisms [32]. Hsu
et al.[ 3 5 ]h a v er e p o r t e dt h a tFAS 1377 allele A was a
protective factor for developing intestinal metaplasia in
the antrum with odds ratio 0.3, while carrying the
FASL 844 allele C was a risk factor for developing gas-
tric atrophy in the corpus with OR of 9.4. The distri-
bution of FAS and FASL genotypes in our cohorts
corresponds to the frequencies reported on Caucasian
subjects in a lung cancer study [45], but we could not
provide any evidence that FAS and FASL gene poly-
morphism are linked with risk for GC or HRAG in
Caucasians.
In the present study we evaluated potential links
between the risk for GC and several carcinogenesis-
related gene polymorphisms that have been rarely or
not described, especially in Caucasian population. We
did not find significant associations between the pre-
sence of GC or HRAG and ACE I/D, NOD1 796G>A,
TLR4 3725G>C, FAS 1377G>A, 670A>G and FASL
844T>C gene polymorphisms. We also analyzed the
genotype frequencies with respect to different histologi-
cal GC types. ACE D/D genotype was less prevalent in
diffuse-type GC than in controls, however the corre-
sponding subgroups of intestinal and diffuse-type GC
are rather small are therefore firm conclusions can not
be drawn. Because the studies on ACE I/D, NOD1
796G>A, TLR4 3725G>C, FAS 1377G>A, 670A>G and
FASL 844T>C polymorphisms remain limited, evalua-
tion of the association with GC and premalignant gastric
lesions requires additional research. Since the strength
of the association may depend on the studied popula-
tion, larger studies of different ethnic groups with differ-
ent genetic profiles are required. The differences in
current data on these polymorphisms may result from
study design, H. pylori prevalence, and different histolo-
gical subtypes of GC. In this study there was no differ-
ence in H. pylori positivity among GC, HRAG and
control groups. The possible explanation for these find-
ings could be higher prevalence of H. pylori in Baltic
countries, when compared to Germany. HRAG and con-
trol groups were selected both in Germany and Baltic
countries, while GC subjects were recruited only in the
German centre, thus possibly affected the H. pylori sta-
tus within the groups. Alterations in various genes,
including oncogenes, tumor-suppressor genes, proin-
flammatory genes, bacterial recognition and cell-adhe-
sion-related genes have been studied in gastric
carcinogenesis [5,24,46]. In previous studies we also
evaluated the role of IL-1B, IL-1RN and NOD2 gene
polymorphisms with respect to risks for GC; however
no significant associations were identified [36-38]. Some
reports suggested that host genetic factors determine
the severity of gastric damage and the eventual clinical
outcome of H. pylori infection [47,48]. These findings
however have not been transferred to daily clinical prac-
tice, and therefore applicable predisposing genetic fac-
tors remain still to be determined.
Conclusions
The study shows that the polymorphisms of ACE,
NOD1, TLR4, FAS and FASL genes are not associated
with H. pylori-induced premalignant gastric conditions
and GC in subjects of Caucasian ethnicity. Based on the
data available now, the investigated polymorphisms are
not applicable for identifying individuals with higher
risk for developing GC.
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